[Intradiverticular bladder tumours: review of the Cancer Committee of the French Association of Urology].
BACKGROUND
Cancer Committee of the French Association of Urology (CCAFU) conducted a review of the epidemiology, diagnosis and treatment of intradiverticular bladder tumours (TVID) and proposed therapeutic management.


METHODS
A bibliographic research in French and English using Medline(®) with the keywords "tumor", "bladder" and "diverticulum" was performed.


RESULTS
TVID are more frequently of stage T ≥ 3a and with non urothelial histology than classical bladder tumors. At diagnosis, the risk of underestimation of the extent and multifocality of the tumor was described. Their prognosis, that was more pejorative than conventional tumors, should impelled to limit the indications of conservative treatment. The evidence levels of analyzed publications were low, with C level according to Sackett score.


CONCLUSIONS
the specificities of the TVID have lead the CCAFU to propose specific therapeutic guidelines, based on poor evidence level. Ta-T1 low grade TVID can be treated by transurethral resection alone or followed by BCG therapy in cases of associated carcinoma in situ. High-grade TVID, unifocal and without associated carcinoma in situ, can be treated by diverticulectomy associated with pelvic lymphadenectomy. High grade TVID, multiple or associated with carcinoma in situ, warranted total cystectomy.
Service d'urologie, hôpital Foch, université de Versailles, 40, rue Worth, Saint-Quentin-en-Yvelines, 92150 Suresnes, France. y.neuzillet@hopital-foch.org
Y
Y
Neuzillet
E
E
Comperat
M
M
Rouprêt
S
S
Larre
C
C
Roy
H
H
Quintens
N
N
Houede
G
G
Pignot
H
H
Wallerand
M
M
Soulie
C
C
Pfister
D001500:BCG Vaccine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D015653:Cystectomy; D003952:Diagnostic Imaging; D004240:Diverticulum / Q000473:pathology*; D006801:Humans; D009367:Neoplasm Staging; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*
D001500:BCG Vaccine